BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31529774)

  • 21. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
    Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
    BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.
    Jelicic J; Juul-Jensen K; Bukumiric Z; Runason Simonsen M; Roost Clausen M; Ludvigsen Al-Mashhadi A; Schou Pedersen R; Bjørn Poulsen C; Ortved Gang A; Brown P; El-Galaly TC; Larsen TS
    Cancer Med; 2024 Jun; 13(12):e7239. PubMed ID: 38888359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
    Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
    Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
    Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
    Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
    Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
    Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.
    Cox MC; Nofroni I; Ruco L; Amodeo R; Ferrari A; La Verde G; Cardelli P; Montefusco E; Conte E; Monarca B; Aloe-Spiriti MA
    Leuk Lymphoma; 2008 Sep; 49(9):1745-51. PubMed ID: 18798109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma.
    Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1804-12. PubMed ID: 25042737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
    Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
    Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
    Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.
    Chen Y; Neelapu S; Feng L; Bi W; Yang TH; Wang M; Fanale MA; Westin JR; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Fowler NH; McLaughlin P; Cabanillas F; Oki Y; Nastoupil LJ; Rodriguez A
    Br J Haematol; 2016 Oct; 175(2):290-299. PubMed ID: 27448187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era.
    Aoki K; Tabata S; Yonetani N; Matsushita A; Ishikawa T
    Acta Haematol; 2013; 130(4):242-6. PubMed ID: 23860478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
    Wen J; Zhou J; Liu Z; Liu T; Xu C
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
    Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
    Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and prognosis of the dynamic monitoring lymphocyte to monocyte ratio in patients with diffuse large B-cell lymphoma].
    Zhang SN; Li MJ; Yuan FF; Chen L; Mi RH; Wei XD; Song YP; Yin QS
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3139-3144. PubMed ID: 31694104
    [No Abstract]   [Full Text] [Related]  

  • 40. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
    Bairey O; Shacham-Abulafia A; Shpilberg O; Gurion R
    Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.